These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 20450612)
1. [Clinical study of Sunitinib in the treatment of metastatic renal clear cell carcinoma: a single center 23 cases experience]. Li XS; Song Y; Gong K; Zhang Q; Yu W; Song G; Zhao Z; Zhang Z; Wang G; Zhou LQ; He ZS; Jin J Zhonghua Wai Ke Za Zhi; 2010 Mar; 48(5):375-7. PubMed ID: 20450612 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma. Li XS; Wu X; Zhao PJ; Huang LH; Song Y; Gong K; Shen C; Yu W; Song G; Zhao Z; Zhang Z; Zhang Q; Wang G; He ZS; Zhou LQ; Jin J Chin Med J (Engl); 2011 Sep; 124(18):2920-4. PubMed ID: 22040503 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of sunitinib in patients with metastatic renal cell carcinoma: initial experience in two Chinese centers. He Z; Guo G; Zhang C; Li X; Fu W; Jin J; Zhang X; Zhou L Chin Med J (Engl); 2014; 127(8):1450-3. PubMed ID: 24762587 [TBL] [Abstract][Full Text] [Related]
4. Sunitinib in metastatic renal cell carcinoma: Experience from single center study, efficacy and safety. Patel KB; Panchal HP; Karanwal AB; Parekh BB; Shah S; Prasad S Indian J Cancer; 2016; 53(1):118-22. PubMed ID: 27146758 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of sunitinib for advanced non-clear cell renal cell carcinoma. Shi HZ; Tian J; Li CL Asia Pac J Clin Oncol; 2015 Dec; 11(4):328-33. PubMed ID: 26471774 [TBL] [Abstract][Full Text] [Related]
7. Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study. Paglino C; Imarisio I; Ganini C; Morbini P; Vercelli A; Bregant C; Porta C Future Oncol; 2012 Dec; 8(12):1605-12. PubMed ID: 23231522 [TBL] [Abstract][Full Text] [Related]
8. Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma. Rautiola J; Utriainen T; Peltola K; Joensuu H; Bono P Acta Oncol; 2014 Jan; 53(1):113-8. PubMed ID: 23721300 [TBL] [Abstract][Full Text] [Related]
9. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma. La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694 [TBL] [Abstract][Full Text] [Related]
10. Sunitinib in patients with metastatic renal cell carcinoma: Birmingham experience. Ansari J; Fatima A; Fernando K; Collins S; James ND; Porfiri E Oncol Rep; 2010 Aug; 24(2):507-10. PubMed ID: 20596640 [TBL] [Abstract][Full Text] [Related]
11. Clinical Experience of Escalated Sunitinib Dose in Select Patients With Metastatic Renal Cell Carcinoma. Shi HZ; Tian J; Chen X; Wang D; Li CL Clin Genitourin Cancer; 2017 Feb; 15(1):139-144. PubMed ID: 27338518 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. Josephs D; Hutson TE; Cowey CL; Pickering LM; Larkin JM; Gore ME; Van Hemelrijck M; McDermott DF; Powles T; Chowdhury P; Karapetis C; Harper PG; Choueiri TK; Chowdhury S BJU Int; 2011 Oct; 108(8):1279-83. PubMed ID: 21244613 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial. Sternberg CN; Calabrò F; Bracarda S; Cartenì G; Lo Re G; Ruggeri EM; Basso U; Gasparini G; Ciuffreda L; Ferrari V; Bonetti A; Fea E; Gasparro D; Tassinari D; Labianca R; Masini C; Fly K; Zhang K; Hariharan S; Capaccetti B; Porta C Oncology; 2015; 88(5):273-80. PubMed ID: 25592399 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency. Kim KH; Kim HY; Kim HR; Sun JM; Lim HY; Lee HJ; Lee S; Bae WK; Rha SY; ; Eur J Cancer; 2014 Mar; 50(4):746-52. PubMed ID: 24332573 [TBL] [Abstract][Full Text] [Related]
15. Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience. Coelho RC; Reinert T; Campos F; Peixoto FA; de Andrade CA; Castro T; Herchenhorn D Int Braz J Urol; 2016; 42(4):694-703. PubMed ID: 27564279 [TBL] [Abstract][Full Text] [Related]
17. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Uemura H; Shinohara N; Yuasa T; Tomita Y; Fujimoto H; Niwakawa M; Mugiya S; Miki T; Nonomura N; Takahashi M; Hasegawa Y; Agata N; Houk B; Naito S; Akaza H Jpn J Clin Oncol; 2010 Mar; 40(3):194-202. PubMed ID: 19897852 [TBL] [Abstract][Full Text] [Related]
18. Central and Eastern European experience with sunitinib in metastatic renal cell carcinoma: a sub-analysis of the global expanded-access trial. Vrdoljak E; Géczi L; Mardiak J; Ciuleanu TE; Leyman S; Zhang K; Sajben P; Torday L Pathol Oncol Res; 2015 Jul; 21(3):775-82. PubMed ID: 25557271 [TBL] [Abstract][Full Text] [Related]
19. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Zimmermann K; Schmittel A; Steiner U; Asemissen AM; Knoedler M; Thiel E; Miller K; Keilholz U Oncology; 2009; 76(5):350-4. PubMed ID: 19321976 [TBL] [Abstract][Full Text] [Related]
20. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Gore ME; Hariharan S; Porta C; Bracarda S; Hawkins R; Bjarnason GA; Oudard S; Lee SH; Carteni G; Nieto A; Yuan J; Szczylik C Cancer; 2011 Feb; 117(3):501-9. PubMed ID: 20862748 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]